Compare PL & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PL | SYRE |
|---|---|---|
| Founded | 2010 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7B | 8.5B |
| IPO Year | 2021 | 2015 |
| Metric | PL | SYRE |
|---|---|---|
| Price | $23.70 | $102.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 12 |
| Target Price | $27.64 | ★ $85.08 |
| AVG Volume (30 Days) | ★ 6.7M | 942.6K |
| Earning Date | 06-03-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $307,727,000.00 | N/A |
| Revenue This Year | $42.29 | N/A |
| Revenue Next Year | $30.22 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 25.94 | N/A |
| 52 Week Low | $6.10 | $14.51 |
| 52 Week High | $51.72 | $108.14 |
| Indicator | PL | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 47.53 | 55.31 |
| Support Level | $19.57 | $92.37 |
| Resistance Level | $27.57 | $104.07 |
| Average True Range (ATR) | 1.40 | 5.63 |
| MACD | 0.73 | -0.22 |
| Stochastic Oscillator | 81.92 | 63.06 |
Planet Labs PBC is an Earth-imaging company. It uses space to help life on Earth by imaging the world every day and making change visible, accessible, and actionable. Its platform includes imagery, insights, and machine learning that empower companies, governments, and communities around the world to make timely decisions about the evolving world. Its solutions are Broad Area Management. Its products are Planet Monitoring, Planet Tasking, Planet Analytic Feeds, Planetary Variables, Planet Basemaps, Planet Insights, and Platform Pricing. The group provides solutions to the Agriculture Science Program, Energy & Infrastructure, Forestry & Land Use, Mapping, Sustainability, Maritime, Civil Government, U.S. State and Local, Europe, Planet Federal, Defense & Intelligence, and Armed Services.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.